1.26
Geron Corp stock is traded at $1.26, with a volume of 6.75M.
It is down -1.56% in the last 24 hours and down -17.11% over the past month.
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.
See More
Previous Close:
$1.28
Open:
$1.3
24h Volume:
6.75M
Relative Volume:
0.66
Market Cap:
$802.52M
Revenue:
$29.48M
Net Income/Loss:
$-201.19M
P/E Ratio:
-3.9375
EPS:
-0.32
Net Cash Flow:
$-216.50M
1W Performance:
+1.61%
1M Performance:
-17.11%
6M Performance:
-58.14%
1Y Performance:
-70.63%
Geron Corp Stock (GERN) Company Profile
Name
Geron Corp
Sector
Industry
Phone
(650) 473-7700
Address
919 EAST HILLSDALE BOULEVARD, FOSTER CITY, CA
Compare GERN with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
GERN
Geron Corp
|
1.26 | 815.25M | 29.48M | -201.19M | -216.50M | -0.32 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Geron Corp Stock (GERN) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jul-10-25 | Resumed | Goldman | Sell |
May-08-25 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
Feb-27-25 | Downgrade | B. Riley Securities | Buy → Neutral |
Feb-26-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
Nov-05-24 | Initiated | H.C. Wainwright | Buy |
Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
Sep-09-24 | Initiated | Leerink Partners | Outperform |
Apr-30-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
Apr-29-24 | Initiated | TD Cowen | Buy |
Mar-15-24 | Reiterated | Needham | Buy |
Sep-12-23 | Upgrade | Goldman | Neutral → Buy |
Mar-28-23 | Initiated | Goldman | Neutral |
Oct-28-22 | Initiated | Wedbush | Outperform |
Jul-28-22 | Resumed | B. Riley Securities | Buy |
Nov-02-21 | Initiated | Robert W. Baird | Outperform |
Feb-18-21 | Resumed | B. Riley Securities | Buy |
Aug-03-20 | Initiated | Stifel | Buy |
Nov-19-19 | Resumed | B. Riley FBR | Buy |
Sep-03-19 | Initiated | H.C. Wainwright | Buy |
Aug-15-19 | Initiated | Cantor Fitzgerald | Overweight |
Apr-09-19 | Upgrade | Needham | Hold → Buy |
Jan-31-19 | Upgrade | B. Riley FBR | Neutral → Buy |
Oct-02-18 | Downgrade | B. Riley FBR | Buy → Neutral |
Jul-05-18 | Initiated | B. Riley FBR, Inc. | Buy |
Sep-13-16 | Reiterated | FBR & Co. | Outperform |
Sep-13-16 | Reiterated | FBR Capital | Outperform |
Dec-07-15 | Reiterated | Piper Jaffray | Overweight |
Apr-21-15 | Initiated | Oppenheimer | Outperform |
Jun-12-14 | Upgrade | MLV & Co | Hold → Buy |
Mar-12-14 | Downgrade | MLV & Co | Buy → Hold |
Dec-10-13 | Reiterated | MLV & Co | Buy |
Dec-10-13 | Upgrade | Needham | Hold → Buy |
Nov-08-13 | Reiterated | MLV & Co | Buy |
Oct-16-13 | Initiated | MLV & Co | Buy |
Aug-30-12 | Initiated | Stifel Nicolaus | Buy |
Jun-28-12 | Initiated | Needham | Hold |
View All
Geron Corp Stock (GERN) Latest News
How high can Geron Corporation stock price go in 2025Market Timing Advice - Metal.it
Geron (GERN.O) Surges 5.08%: What’s Driving the Intraday Rally? - AInvest
What analysts say about Geron Corporation stockOutstanding stock performance - jammulinksnews.com
Market Sentiment Around Loss-Making Geron Corporation (NASDAQ:GERN) - simplywall.st
Geron Corporation Stock Analysis and ForecastOutstanding capital returns - jammulinksnews.com
Geron Corporation (GERN) Plunges 3.88% to 2025 Low on Earnings Miss - AInvest
Commercial Stage Biotech Geron Expands Team with 342,000 Share Equity Package for Strategic New Hires - Stock Titan
Why Geron Corporation stock attracts strong analyst attentionTechnical Breakout List - Newser
What makes Geron Corporation stock price move sharplyTriple Return With Stability - Newser
Geron Presents Positive RYTELO Data for LR-MDS at ASCO & EHA, Highlights Efficacy, Myelofibrosis Program Progress - Insider Monkey
Geron Corporation (NASDAQ:GERN) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World
Geron (NASDAQ:GERN) Shares Gap Down – Here’s Why - Defense World
Cambridge Investment Research Advisors Inc. Cuts Stock Position in Geron Corporation (NASDAQ:GERN) - Defense World
Here’s Why Geron Corp. (NASDAQ:GERN) Crashed Today - MSN
Geron resumed with a Sell at Goldman Sachs - TipRanks
Geron Corp’s Rytelo Faces Market Challenges and Declining Physician Adoption, Supporting Sell Rating - TipRanks
Goldman Sachs resumes Geron stock coverage with Sell rating on weak Rytelo sales - Investing.com
Geron Corp (GERN) Stock: A Year of Highs and Lows - investchronicle.com
Leerink Partners Reiterates a Buy Rating on Geron Corporation (GERN) - MSN
13 Stocks Under $5 With High Upside Potential - Insider Monkey
DSS switches auditors to HTL; no disputes with Grassi reported | GERN SEC FilingForm 4 - Stock Titan
Geron Corporation(NasdaqGS: GERN) dropped from Russell 2500 Value Index - MarketScreener
Geron Corporation(NasdaqGS: GERN) dropped from Russell Small Cap Comp Value Index - MarketScreener
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Geron Expands Team with 16 New Hires, Awards Over $1.6M in Stock Options and RSUs - Stock Titan
With 65% institutional ownership, Geron Corporation (NASDAQ:GERN) is a favorite amongst the big guns - Yahoo Finance
Geron: A Tough First Year For Rytelo, But Not Yet Time To Sell (Downgrade) (NASDAQ:GERN) - Seeking Alpha
Favourable Signals For Geron: Numerous Insiders Acquired Stock - simplywall.st
Geron Q1 2025 slides: RYTELO growth plans amid revenue challenges - Investing.com
Geron Q1 2025 slides: RYTELO growth plans amid revenue challenges By Investing.com - Investing.com Canada
Geron Corporation Reports First Quarter 2025 Financial Results and Recent Business Highlights - mx.advfn.com
Class Action Filed Against Geron Corporation (GERN)May 12, 2025 Deadline to JoinContact The Gross Law Firm - mx.advfn.com
Conservative Vision Of A Positive Future For Geron (NASDAQ:GERN) - Seeking Alpha
Is Geron Corporation Stock a Bargain Now? - StocksToTrade
Nuveen Asset Management LLC Purchases 14,657 Shares of Geron Co. (NASDAQ:GERN) - Defense World
Geron showcases RYTELO benefits at oncology meetings By Investing.com - Investing.com South Africa
Geron’s SWOT analysis: oncology firm’s stock faces growth hurdles By Investing.com - Investing.com South Africa
Geron showcases RYTELO benefits at oncology meetings - Investing.com
Geron Announces Presentations at ASCO and EHA Underscoring RYTELO® (imetelstat) Efficacy and Safety Across Range of LR-MDS Patients, and Showcasing Momentum of Myelofibrosis Program - Yahoo Finance
Geron’s SWOT analysis: oncology firm’s stock faces growth hurdles - Investing.com
Geron Corp stockholders approve equity plan amendments By Investing.com - Investing.com India
Geron Corp stockholders approve equity plan amendments - Investing.com
BNP Paribas Financial Markets Decreases Stock Holdings in Geron Co. (NASDAQ:GERN) - Defense World
25,148 Shares in Geron Co. (NASDAQ:GERN) Purchased by Lazard Asset Management LLC - Defense World
Geron Co. (NASDAQ:GERN) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
Bank of America Corp DE Boosts Stock Position in Geron Co. (NASDAQ:GERN) - Defense World
Investigation announced for Long-Term Investors in shares - openPR.com
Ameriprise Financial Inc. Buys 247,018 Shares of Geron Co. (NASDAQ:GERN) - Defense World
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | GERN Stock News - GuruFocus
Geron Grants $522K Worth of Stock Options and RSUs: New Employee Compensation Details Revealed - Stock Titan
Stifel Financial Corp Increases Position in Geron Co. (NASDAQ:GERN) - Defense World
Geron Corp Stock (GERN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Geron Corp Stock (GERN) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Samuels Scott Alan | EVP, Chief Legal Officer |
Feb 27 '25 |
Buy |
1.61 |
15,000 |
24,150 |
26,682 |
SCARLETT JOHN A | Chairman, President and CEO |
Feb 27 '25 |
Buy |
1.76 |
12,500 |
22,062 |
12,500 |
Ziegler James | EVP, Chief Commercial Officer |
Feb 27 '25 |
Buy |
1.60 |
100,000 |
160,000 |
100,000 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):